Drug Profile

D 2570

Alternative Names: D-2570

Latest Information Update: 23 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator InventisBio
Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Small molecules
Mechanism of Action TYK2 kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase III Plaque psoriasis
Phase II Psoriatic arthritis; Ulcerative colitis

Most Recent Events

17 Feb 2026 InventisBio plans a phase I mass balance study in healthy subjects in March 2026 (NCT07411742)
08 Jan 2026 InventisBio plans the phase III D2570-302 trial for Plaque psoriasis in China (PO, Tablet) , (NCT07326813)
30 Dec 2025 InventisBio plans a phase II trial for Systemic lupus erythematosus (Treatment-experienced) in January 2026 (PO) (NCT07311200)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com